Top

Published in:

Open Access 01-02-2003 | Research article

Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer

Authors: Hiroko Yamashita, Mariko Nishio, Tatsuya Toyama, Hiroshi Sugiura, Zhenhuan Zhang, Shunzo Kobayashi, Hirotaka Iwase

Published in: Breast Cancer Research | Issue 1/2003

Abstract

Introduction

Many laboratories are currently evaluating the usefulness of determination of HER2, p53, and Ki67 proliferation indices using immunohistochemical techniques in cancer. Although the available studies suggest that these factors might indeed be helpful in making treatment decisions in cancer patients, their clinical usefulness is still controversial.

Methods

Expression of HER2, p53, and Ki67 was examined by immunohistochemistry in samples of breast tissue from 506 patients with invasive ductal carcinoma, obtained between 1981 and 1999 (median follow up period 82 months), and their significance for prognosis was analyzed.

Results

Of the 506 carcinoma tissue samples, 20.1%, 29.0%, and 53.6% were positive for HER2 over-expression, p53 protein accumulation, and Ki67 expression, respectively. Over-expression of HER2 significantly reduced disease free (P = 0.02) and overall survival (P = 0.005). Accumulation of p53 protein significantly decreased disease free (P = 0.01) and overall survival (P = 0.01). Patients with tumors that were positive for both HER2 and p53 relapsed and died within a significantly shorter period of time after surgery (P = 0.0001 and P < 0.0001, respectively). In multivariate analysis, patients with both HER2 and p53 positive tumors had considerably decreased overall survival (P = 0.04), as did patients with larger tumor size and positive lymph node status.

Conclusion

The findings of the present study indicate that the coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.

Available only for authorised users

Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11: 155-168.PubMed

Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999, 17: 3058-3063.PubMed

Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000, 124: 966-978.PubMed

Kobayashi S, Iwase H, Ito Y, Yamashita H, Iwata H, Yamashita T, Ito K, Toyama T, Nakamura T, Masaoka A: Clinical significance of bcl-2 gene expression in human breast cancer tissues. Breast Cancer Res Treat. 1997, 42: 173-181. 10.1023/A:1005760013810.CrossRefPubMed

Yamashita H, Kobayashi S, Iwase H, Itoh Y, Kuzushima T, Iwata H, Itoh K, Naito A, Yamashita T, Masaoka A, Kimura N: Analysis of oncogenes and tumor suppressor genes in human breast cancer. Jpn J Cancer Res. 1993, 84: 871-878.CrossRefPubMed

Hamilton A, Piccart M: The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol. 2000, 11: 647-663. 10.1023/A:1008390429428.CrossRefPubMed

Iwase H, Ando Y, Ichihara S, Toyoshima S, Nakamura T, Karamatsu S, Ito Y, Yamashita H, Toyama T, Omoto Y, Fujii Y, Mitsuyama S, Kobayashi S: Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast. Breast Cancer. 2001, 8: 98-104.CrossRefPubMed

Kobayashi S, Iwase H, Itoh Y, Fukuoka H, Yamashita H, Kuzushima T, Iwata H, Masaoka A, Kimura N: Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancers. Jpn J Cancer Res. 1992, 83: 859-865.CrossRefPubMed

Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Price P, McKinna A, Harrison S: Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Int J Cancer. 1988, 42: 842-845.CrossRefPubMed

10.

Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999, 17: 1474-1481.PubMed

11.

Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986, 232: 1644-1646.CrossRefPubMed

12.

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182.CrossRefPubMed

13.

Hurlimann J, Chaubert P, Benhattar J: p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Mod Pathol. 1994, 7: 423-428.PubMed

14.

Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC, Iglehart JD, Marks JR: p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem. 1992, 40: 1047-1051.CrossRefPubMed

15.

Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993, 85: 200-206.CrossRefPubMed

16.

Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992, 84: 845-855. 10.1093/jnci/84.11.845.CrossRefPubMed

17.

Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, Krontiras H, Urist MM, Bland KI: Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg. 2001, 233: 630-638. 10.1097/00000658-200105000-00006.CrossRefPubMedPubMedCentral

18.

Rahko E, Blanco G, Soini Y, Bloigu R, Jukkola A: A mutant TP53 gene status is associated with a poor prognosis and anthra-cycline-resistance in breast cancer patients. Eur J Cancer. 2003, 39: 447-453. 10.1016/S0959-8049(02)00499-9.CrossRefPubMed

19.

Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998, 16: 462-469.PubMed

20.

Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, Iglehart JD: Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg. 1994, 219: 332-341.CrossRefPubMedPubMedCentral

21.

Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, Keramopoulos A: Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. J Pathol. 1996, 179: 31-38. 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O.CrossRefPubMed

22.

Tsuda H, Sakamaki C, Tsugane S, Fukutomi T, Hirohashi S: A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. Breast Cancer Res Treat. 1998, 48: 21-32. 10.1023/A:1005977630830.CrossRefPubMed

23.

Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L: p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol. 1995, 13: 821-830.PubMed

24.

Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res. 1998, 4: 7-12.PubMed

25.

Yamauchi H, Stearns V, Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001, 19: 2334-2356.PubMed

26.

Stal O, Borg A, Ferno M, Kallstrom AC, Malmstrom P, Nordenskjold B: ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol. 2000, 11: 1545-1550. 10.1023/A:1008313310474.CrossRefPubMed

27.

Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992, 10: 599-605.PubMed

28.

Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992, 10: 1049-1056.PubMed

29.

Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998, 90: 1346-1360. 10.1093/jnci/90.18.1346.CrossRefPubMed

30.

Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998, 90: 1361-1370. 10.1093/jnci/90.18.1361.CrossRefPubMed

31.

Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan CH, Ries F, Gobert PH, Closon-Dejardin MT, Dolci S, Rouas G, Paesmans M, Lobelle JP, Isola J, Piccart MJ: HER-2 and topoisomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol. 2001, 12: 1081-1089. 10.1023/A:1011669223035.CrossRefPubMed

Title: Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer
Authors: Hiroko Yamashita
Mariko Nishio
Tatsuya Toyama
Hiroshi Sugiura
Zhenhuan Zhang
Shunzo Kobayashi
Hirotaka Iwase
Publication date: 01-02-2003
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 1/2003
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr738

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2003

Expression of androgen receptor and prostate-specific antigen in male breast carcinoma

Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments

Breast Cancer Therapy Annual – today's drug treatment of cancer?

The diagnosis and management of pre-invasive breast disease: another point of view

Introducing the concept of breast cancer stem cells

Interleukin-2 and its receptor complex (α, β and γ chains) in in situand infiltrative human breast cancer: an immunohistochemical comparative study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer